Acute coronary syndromes, defined as myocardial infarction withST-segment elevation, myocardial infarction without ST-segmentelevation, and unstable angina, share a common pathophysiology:atherosclerotic plaque rupture, erosion, or both with superimposedintracoronary thrombosis, commonly known as atherothrombosis.1Two large randomized trials reported in this issue of the Journal2,3address the evolving use of antithrombotic agents for thesesyndromes; a third trial has been published recently.4
Table 1 places these trials in the context of existing practiceguidelines for antithrombotic agents. The oldest antithromboticagent is unfractionated heparin. Although treatment with unfractionatedheparin is generally indicated for 24 to 48 hours in . . . [Full Text of this Article]
Source Information
From the Mayo Clinic College of Medicine, Rochester, Minn. (R.J.G.); and Mt. Sinai School of Medicine, New York (V.F.).
This article was published at www.nejm.org on March 14, 2006.
This article has been cited by other articles:
LaPointe, N. M. A., Chen, A. Y., Alexander, K. P., Roe, M. T., Pollack, C. V. Jr, Lytle, B. L., Ohman, M. E., Gibler, B. W., Peterson, E. D.
(2007). Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes. Arch Intern Med
167: 1539-1544
[Abstract][Full Text]
(2006). Anticoagulants in Acute Coronary Syndromes: More Progress. JWatch Emergency Med.
2006: 3-3
[Full Text]
(2006). Fondaparinux for Acute Coronary Syndromes. JWatch General
2006: 3-3
[Full Text]
(2006). Unfractionated or LMW Heparin in Conjunction with Fibrinolysis?. JWatch General
2006: 5-5
[Full Text]